lobbying_activities: 3330999
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3330999 | 6035677c-67c9-4225-a936-bb73e2cf17ae | Q1 | ALPINE GROUP PARTNERS, LLC. | 1171 | EMERGENT BIOSOLUTIONS | 2025 | first_quarter | AVI | Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY25 and FY26; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY25 and FY26; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY25 and FY26; NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone; H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025 | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2025-04-10T13:12:41-04:00 |